New Diabetes Drug Shows Promise in FDA-Approved Trial Starting 2026

A new oral diabetes medication called ASC30 has received FDA approval to begin human trials in 2026, offering hope for the millions of Americans struggling with type 2 diabetes. The drug works by mimicking a natural hormone called glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels, but it's designed to be taken as a daily pill rather than an injection.

What Makes This Diabetes Drug Different?

ASC30 stands out because it's what researchers call a "fully biased agonist," meaning it's engineered to activate specific pathways that control blood sugar without triggering as many digestive side effects. In a recent 13-week study for weight loss, participants taking ASC30 experienced significantly less vomiting compared to similar medications - about half the rate seen with other GLP-1 drugs.

The upcoming diabetes trial will test three different doses of ASC30 in approximately 100 people with type 2 diabetes across multiple U.S. locations. Participants will start with a low 1 mg dose and gradually increase to their target dose over several weeks to minimize side effects.

How Will Researchers Measure Success?

The primary goal is to see how well ASC30 reduces hemoglobin A1C (HbA1c), a blood test that shows average blood sugar levels over the past two to three months. Doctors typically aim for an A1C below 7% for most adults with diabetes. The study will also track several other important measures:

• Fasting Blood Glucose: How well the drug controls blood sugar levels after an overnight fast
• Body Weight Changes: Whether participants lose weight, which often helps improve diabetes control
• Safety Profile: Monitoring for side effects and how well people tolerate the medication

"IND clearance for this Phase II study for diabetes is a significant milestone for Ascletis as we continue to build upon the data for ASC30," said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis. "Furthermore, the FDA's clearance of our IND expands entry for ASC30 into clinical development for the large diabetes treatment market."

What This Could Mean for People with Diabetes?

If successful, ASC30 could provide an alternative to current diabetes medications that often come with challenging side effects. Many existing GLP-1 drugs require injections and can cause significant nausea and vomiting, leading some people to stop treatment. The company's previous weight loss study showed a treatment discontinuation rate of just 4.8% due to adverse events, suggesting better tolerability.

The trial is expected to begin enrollment in the first quarter of 2026, with results potentially available by mid-2026. While it's still early in development, ASC30 represents a new approach to diabetes treatment that could offer better blood sugar control with improved quality of life for patients who struggle with current options.